Newsfeeds - Spark Newswire

1 minute read

Earnings

Return on Capital Employed Overview: Pulmonx

August 20, 1:52 PM

After pulling data from Benzinga Pro it seems like during Q2, Pulmonx (NASDAQ:LUNG) brought in sales totaling $12.20 million. However, earnings decreased 0.58%, resulting in a loss of $12.10 million.

LUNG

1 minute read

Canaccord Genuity Maintains Buy on Pulmonx, Lowers Price Target to $53

By Benzinga Newsdesk

August 4, 12:14 PM

Canaccord Genuity analyst William Plovanic maintains Pulmonx (NASDAQ:LUNG) with a Buy and lowers the price target from $65 to $53.

LUNG

1 minute read

Pulmonx Q2 EPS $(0.34) Up From $(0.37) YoY, Sales $12.20M Beat $10.51M Estimate

By Bill Haddad

August 3, 4:47 PM

Pulmonx (NASDAQ:LUNG) reported quarterly losses of $(0.34) per share. This is a 8.11 percent increase over losses of $(0.37) per share from the same period last year. The company reported quarterly sales of $12.20

LUNG

6 minute read

The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly’s Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business

By Shanthi Rexaline

August 3, 7:55 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2)

ABSI

21 minute read

Earnings Scheduled For August 3, 2021

By Benzinga Insights

August 3, 3:52 AM

Companies Reporting Before The Bell • Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter. • Stellantis (NYSE:STLA) is expected to report earnings for its second quarter.

AAIC

6 minute read

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs

By Shanthi Rexaline

August 1, 10:13 AM

Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.

ABUS

5 minute read

Uncategorized

The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts

By Shanthi Rexaline

May 14, 7:59 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13)

ACHL

20 minute read

Uncategorized

Earnings Scheduled For May 4, 2021

By Benzinga Insights

May 4, 4:21 AM

Companies Reporting Before The Bell • Lancaster Colony (NASDAQ:LANC) is likely to report quarterly earnings at $1.24 per share on revenue of $340.02 million.

ACLS